# US 2024/0391887 A1 · New VASHs inhibitors, conjugates thereof and their uses as drugs or as research tools

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391887 A1
- Document ID: US20240391887A1
- Status: Published application
- Kind: A1
- Application number: 18/686,411
- Filed: 2022-08-24
- Published: 2024-11-28
- Earliest claimed: 2021-08-24
- Assignees: Centre National de Recherche Scientifique (CNRS); Universite De Montpellier; Ecole Nationale Superieure De Chimie De Montpellier; Mt Act
- Applicants: Centre National de Recherche Scientifique (CNRS); Universite de Montpellier; Ecole Nationale Superieure de Chimie de Montpellier; Mt Act
- Inventors: Krzysztof ROGOWSKI; Muriel AMBLARD-CAUSSIL; Siem VAN DER LAAN; Lubomir VEZENKOV; Guillaume MARCELLIN; Yoann LANNAY; Khaled HACHED
- Web page: https://patentgrep.com/patent/US20240391887A1

## CPC

- C07D 303/48: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/16: Anti-Parkinson drugs
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C12Q 1/37: involving peptidase or proteinase
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt and/or solvate thereof,
in which
X is
R1 is O—C1-C6 alkyl, O—C2-C6 alkenyl, NR1aR1b or
R1a is H or a C1-C6 alkyl,
R1b is OH or C1-C6 alkyl, said alkyl being optionally substituted with C(O)OH, C(O)O—C1-C6 alkyl or an aryl,
R is O—R2 or NH—S(O)2—R9,
R2 is H, a C1-C6 aliphatic chain, aryl, heteroaryl or C1-C6 alkyl-aryl, wherein up to 4 methylene units of said aliphatic chain are optionally replaced by O, C(O), NH or N—C1-C6alkyl, said aliphatic chain, aryl, heteroaryl or alkyl-aryl being optionally substituted,
R3 is OH, O—C1-C6 aliphatic chain, O-aryl, O—C1-C6 alkyl-aryl, O-heteroaryl, O—C1-C6 alkyl-heteroaryl or NHOH, wherein up to 4 methylene units of said aliphatic chain are optionally replaced by O, C(O), NH or N—C1-C6alkyl, said aliphatic chain, aryl, heteroaryl, alkyl-heteroaryl or alkyl-aryl being optionally substituted,
R4 is H or a C1-C12 aliphatic chain wherein up to 4 methylene units are optionally replaced by O, C(O), NH or N—C1-C6alkyl, said C1-C12 aliphatic chain being optionally substituted,
Y is —(CH2)m— or
R5 is OH, O—C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, O—C1-C6 alkyl-aryl, O—C1-C6 alkyl-heteroaryl, C(O)OH, C(O)O—C1-C6 alkyl, C(O)NHOH, C(O)NH2, C(O)NH—C1-C6 alkyl, C(O)NH—O—C1-C6 alkyl, NH—C1-C6 alkyl, N(C1-C6 alkyl)2, NH—C(O)—C1-C6 alkyl or NH—S(O)2—R9, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkyl-aryl or alkyl-heteroaryl being optionally substituted,
R6 is OH, O—C1-C6 aliphatic chain, NH—OH or NH—CH(R7)—(CH2)n—R8, said aliphatic chain being optionally substituted,
R7 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, C1-C6 alkyl-aryl or C1-C6 alkyl-heteroaryl,
R8 is C(O)NH2, C(O)NH—C1-C6 alkyl, aryl, heteroaryl, SH, NH2 or S—C1-C6alkyl, and m and n are each independently an integer ranging from 0 to 6,
R9 is a C1-C6 aliphatic chain or an aryl, said aliphatic chain or aryl being optionally substituted,
provided that when X is
and R3 is OH, R1 is not O—C1-C6 alkyl, and compound of formula (I) is not

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R is OR2.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein R2 is H, an optionally substituted C1-C6 alkyl or an optionally substituted C1-C6 alkyl-aryl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R3 is OH, O—C1-C6 aliphatic chain, O—C1-C6 alkyl-aryl, or NHOH, said aliphatic chain being optionally substituted.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1 is O—C1-C6 alkyl, O—C2-C6 alkenyl or NR1aR1b, R1a and R1b being as defined in claim 1.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R1 is
with Y, R5, and R6 being as defined in claim 1.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein Y is
R5 is OH, O—C1-C6 alkyl, O—C1-C6 alkyl-aryl, C(O)NH—O—C1-C6 alkyl, or NH(S(O)2—R9, and R6 is OH or O—C1-C6 alkyl.

### Claim 8 (depends on 6)

The compound according to claim 6, wherein Y is —(CH2)m—, R5 is C(O)OH, C(O)OEt or C(O)NHOH, R6 is NH—CH(R7)—(CH2)n—R8, R7 is H, C1-C6 alkyl, C1-C6 alkyl-aryl, or C1-C6 alkyl-heteroaryl, R8 is C(O)NH2, aryl, heteroaryl, SH, or S—C1-C6alkyl, and n is 0, 1, 2 or 3.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein X is

### Claim 10 (depends on 1)

The compound according to claim 1, responding to the following formula (I-A′):

### Claim 11 (depends on 1)

The compound according to claim 1, being selected from the following compounds:
and the pharmaceutically acceptable salts and/or solvates thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising at least one compound of formula (I) as defined in claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method for treating a VASH peptidase activity associated disorder comprising the administration to a person in need thereof of an effective dose of a compound according to claim 1 or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the VASH peptidase activity associated disorder is a disorder involving altered microtubule detyrosination and/or polyglutamylation.

### Claim 16 (depends on 1)

A conjugate comprising a fragment of a compound of formula (I) as defined in claim 1 linked to a biomolecule.

### Claim 17

(canceled)

### Claim 18 (depends on 1, 16)

Use of compound according to claim 1 or a conjugate according to claim 16 as research tool for research and development activities.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the VASH peptidase activity associated disorder is selected from neurodegenerative diseases, glaucoma, psychiatric disorders, neuronal disorders, cancers, muscular dystrophies, infertility, retinal degeneration, Purkinje cell sicknesses, infantile onset degeneration, male infertilities, and ciliopathies.

### Claim 20 (depends on 16)

The conjugate according to claim 16, wherein the biomolecule is selected from a peptide, a protein, a biomarker, an affinity probe, or a E3 ubiquitin ligase recruiter.

### Claim 21 (depends on 18)

The use of claim 18, wherein research and development activities are selected in the group consisting of:
in vitro and/or in cellulo screening assays for identifying new VASH inhibitors and/or quantifying their inhibitor efficiency,
in vitro method for studying the role of tubulin detyrosination,
in vitro diagnostic methods for identifying or monitoring a VASH peptidase activity associated disorder involving altered microtubule detyrosination and/or polyglutamylation,
and related kits for performing said screening assays and methods.
